Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2020 | Treatment strategies for cHL patients after auto-HSCT

Anna Sureda • 24 Aug 2020
EBMT 2020
Hodgkin Lymphoma Lymphoma Brentuximab vedotin CAR-T Pembrolizumab

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses different treatment strategies for patients with classical Hodgkin lymphoma (cHL) that relapse or progress after autologous-hematopoietic stem cell transplant (auto-HSCT). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anna Sureda

Ask the Expert: Anna Sureda answers your lymphoma questions at EHA 2025 8:15
Ask the Expert: Anna Sureda answers your lymphoma questions at EHA 2025
Anna Sureda • 14 Jun 2025
The potential of Glofit-GemOx as a new standard of care in R/R DLBCL 1:32
The potential of Glofit-GemOx as a new standard of care in R/R DLBCL
Anna Sureda • 31 Mar 2025
Optimizing bridging therapy strategies before CAR T-cell therapy 2:10
Optimizing bridging therapy strategies before CAR T-cell therapy
Anna Sureda • 31 Mar 2025
EBV+ PTLD: clinical perspectives & insights into EBV-driven cell therapy 2:01
EBV+ PTLD: clinical perspectives & insights into EBV-driven cell therapy
Anna Sureda • 31 Mar 2025

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals